Related Projects

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies is a consortium of 16 European institutions, funded by FP7, to carry out research studies into late effects of treatment for cancer, to establish guidelines for follow-up, and to disseminate the results and provide training and workshops for stakeholders. The benefit is to provide every European childhood cancer survivor with better access to care and better long-term health.

ENCCA is an FP7-funded project that aims to efficiently structure and enhance collaboration within the field of paediatric oncology in Europe. To achieve this mission, ENCCA will limit knowledge fragmentation and improve communication channels by bringing together existing informal paediatric and adolescent oncology clinical trial groups, integrating all relevant stakeholders, their expertise and viewpoints to ensure that the project is all-encompassing while remaining patient-centred. Finally, ENCCA will also create a sustainable "European Virtual Institute" for clinical and translational research in childhood and adolescent cancers.

The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is the only pan-European organisation representing all professionals working in the field of childhood cancers. With more than 1,200 members across Europe, today SIOPE is leading the way to ensure the best possible care and outcomes for all children and adolescents with cancer in Europe.

ExPO-r-Net is a 3-year project that will build a European Reference Network (ERN) for Paediatric Oncology. ExPO-r-NeT aims to reduce the current inequalities in childhood cancer survival and healthcare capabilities in different EU Member States.

The EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC project) is a coalition of clinical study groups bringing together the most active clinicians and scientists in Europe dedicated to improving survival from Ewing Sarcoma.

This initiative will support an integrated programme of investigator-driven, inclusive clinical trials that are rigorously designed, conducted, analysed and reported, and underpinned by complementary embedded translational research.

The EEC will provide ES patients with greater access to clinical trials, allow efficient acquisition of knowledge and deliver clinically meaningful results within 5 years, thereby contributing to improved survival from ES.